Bristol-Myers Squibb is set to release its Q1 2025 earnings, with analysts predicting $1.55 EPS and $10.77 billion in revenue. In its last earnings report, the company beat estimates with a $1.67 EPS, ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...

In the phase III ARISE trial, adjunctive xanomeline and trospium chloride (Cobenfy) were no better than placebo at improving ...

The "Brain Tumor Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Brain Tumor Therapeutics was valued at US$1.9 Billion ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

U.S. stock indexes rallied at midday Wednesday as President Donald Trump said he has "no intention" of firing Federal Reserve ...

Bristol-Myers Squibb (NYSE: BMY) is scheduled to announce Q1 earnings results on Thursday, April 24th, before market open.

Bristol Myers Squibb’s schizophrenia drug Cobnefy failed to meet a primary goal in a phase 3 trial, possibly clouding the drug’s future development. The trial evaluated Cobnefy as an add-on therapy to ...

Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said ...